MedTrace Logo

Clinical Trials

Showing trials with last updates posted in 2026.

NCT02839707 | ACTIVE_NOT_RECRUITING | PHASE2/PHASE3
444 participants

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-28
Start Date:
2017-06-23
Completion:
2023-05-09
Conditions
  • Fallopian Tube High Grade Serous Adenocarcinoma
  • Ovarian High Grade Serous Adenocarcinoma
  • Ovarian Seromucinous Carcinoma
  • Primary Peritoneal High Grade Serous Adenocarcinoma
  • Recurrent Fallopian Tube Carcinoma
  • Recurrent Fallopian Tube Clear Cell Adenocarcinoma
  • Recurrent Fallopian Tube Endometrioid Adenocarcinoma
  • Recurrent Fallopian Tube Undifferentiated Carcinoma
  • Recurrent Ovarian Carcinoma
  • Recurrent Ovarian Clear Cell Adenocarcinoma
  • Recurrent Ovarian Endometrioid Adenocarcinoma
  • Recurrent Ovarian Undifferentiated Carcinoma
  • Recurrent Platinum-Resistant Fallopian Tube Carcinoma
  • Recurrent Platinum-Resistant Ovarian Carcinoma
  • Recurrent Platinum-Resistant Primary Peritoneal Carcinoma
  • Recurrent Primary Peritoneal Carcinoma
  • Recurrent Primary Peritoneal Clear Cell Adenocarcinoma
  • Recurrent Primary Peritoneal Endometrioid Adenocarcinoma
  • Recurrent Primary Peritoneal Undifferentiated Carcinoma
Interventions
  • DRUG
  • BIOLOGICAL
  • PROCEDURE
  • OTHER
Results Available
NCT02639325 | RECRUITING
100 participants

Tumor Related Epilepsy

Study Type:
OBSERVATIONAL
Last Updated:
2026-08-28
Start Date:
2016-01-26
Completion:
2032-07-01
Conditions
  • Epilepsy
  • Cancer
  • Brain Neoplasm
No Results Yet
NCT02595944 | ACTIVE_NOT_RECRUITING | PHASE3
903 participants

Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-28
Start Date:
2016-07-22
Completion:
2026-12-31
Conditions
  • Stage IB Lung Non-Small Cell Carcinoma AJCC v7
  • Stage II Lung Non-Small Cell Cancer AJCC v7
  • Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Interventions
  • PROCEDURE
  • BIOLOGICAL
  • OTHER
No Results Yet
NCT02567435 | ACTIVE_NOT_RECRUITING | PHASE3
325 participants

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-28
Start Date:
2016-06-01
Completion:
2023-06-30
Conditions
  • Alveolar Rhabdomyosarcoma
  • Botryoid-Type Embryonal Rhabdomyosarcoma
  • Embryonal Rhabdomyosarcoma
  • Rhabdomyosarcoma
  • Sclerosing Rhabdomyosarcoma
  • Spindle Cell Rhabdomyosarcoma
Interventions
  • DRUG
  • BIOLOGICAL
  • OTHER
  • RADIATION
Results Available
NCT02506153 | ACTIVE_NOT_RECRUITING | PHASE3
1301 participants

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-28
Start Date:
2015-11-10
Completion:
2023-09-15
Conditions
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • Clinical Stage IV Cutaneous Melanoma AJCC v8
  • Metastatic Cutaneous Melanoma
  • Metastatic Mucosal Melanoma
  • Metastatic Non-Cutaneous Melanoma
  • Non-Cutaneous Melanoma
  • Recurrent Cutaneous Melanoma
  • Recurrent Mucosal Melanoma
  • Recurrent Non-Cutaneous Melanoma
Interventions
  • PROCEDURE
  • BIOLOGICAL
  • OTHER
Results Available
NCT02465060 | ACTIVE_NOT_RECRUITING | PHASE2
6452 participants

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-28
Start Date:
2015-08-17
Completion:
2026-12-31
Conditions
  • Advanced Lymphoma
  • Advanced Malignant Solid Neoplasm
  • Bladder Carcinoma
  • Breast Carcinoma
  • Cervical Carcinoma
  • Colon Carcinoma
  • Colorectal Carcinoma
  • Endometrial Carcinoma
  • Esophageal Carcinoma
  • Exocrine Pancreas Carcinoma
  • Gastric Carcinoma
  • Glioma
  • Head and Neck Carcinoma
  • Hematopoietic and Lymphoid Cell Neoplasm
  • Kidney Carcinoma
  • Liver Carcinoma
  • Lung Carcinoma
  • Lymphoma
  • Malignant Uterine Corpus Neoplasm
  • Malignant Uterine Neoplasm
  • Melanoma
  • Multiple Myeloma
  • Ovarian Carcinoma
  • Prostate Carcinoma
  • Rectal Carcinoma
  • Recurrent Bladder Carcinoma
  • Recurrent Breast Carcinoma
  • Recurrent Cervical Carcinoma
  • Recurrent Colon Carcinoma
  • Recurrent Colorectal Carcinoma
  • Recurrent Esophageal Carcinoma
  • Recurrent Gastric Carcinoma
  • Recurrent Glioma
  • Recurrent Head and Neck Carcinoma
  • Recurrent Liver Carcinoma
  • Recurrent Lung Carcinoma
  • Recurrent Lymphoma
  • Recurrent Malignant Solid Neoplasm
  • Recurrent Malignant Uterine Corpus Neoplasm
  • Recurrent Melanoma
  • Recurrent Multiple Myeloma
  • Recurrent Ovarian Carcinoma
  • Recurrent Pancreatic Carcinoma
  • Recurrent Prostate Carcinoma
  • Recurrent Rectal Carcinoma
  • Recurrent Skin Carcinoma
  • Recurrent Thyroid Gland Carcinoma
  • Refractory Lymphoma
  • Refractory Malignant Solid Neoplasm
  • Refractory Multiple Myeloma
  • Skin Carcinoma
  • Thyroid Gland Carcinoma
Interventions
  • DRUG
  • PROCEDURE
  • OTHER
  • BIOLOGICAL
No Results Yet
NCT02311933 | ACTIVE_NOT_RECRUITING | PHASE2
81 participants

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-28
Start Date:
2015-05-28
Completion:
2020-11-06
Conditions
  • Recurrent Breast Carcinoma
  • Stage III Breast Cancer AJCC v7
  • Stage IIIA Breast Cancer AJCC v7
  • Stage IIIB Breast Cancer AJCC v7
  • Stage IIIC Breast Cancer AJCC v7
  • Stage IV Breast Cancer AJCC v6 and v7
Interventions
  • DRUG
  • OTHER
Results Available
NCT02257528 | ACTIVE_NOT_RECRUITING | PHASE2
26 participants

Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-28
Start Date:
2015-05-18
Completion:
2019-03-05
Conditions
  • Cervical Adenocarcinoma
  • Cervical Adenosquamous Carcinoma
  • Recurrent Cervical Carcinoma
  • Stage IV Cervical Cancer AJCC v6 and v7
  • Stage IVA Cervical Cancer AJCC v6 and v7
  • Stage IVB Cervical Cancer AJCC v6 and v7
Interventions
  • OTHER
  • BIOLOGICAL
Results Available
NCT02224781 | ACTIVE_NOT_RECRUITING | PHASE3
267 participants

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-28
Start Date:
2015-09-08
Completion:
2023-09-30
Conditions
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • Clinical Stage IV Cutaneous Melanoma AJCC v8
  • Metastatic Melanoma
  • Recurrent Melanoma
  • Unresectable Melanoma
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
  • OTHER
Results Available
Previous
Sorted by latest updates
Next
Showing 40 trials per page